Sutro Biopharma names new director
9 November 2018 -

Sutro Biopharma Inc (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company in the United States, has named Shalini Sharp as its new director.

Sharp was chief financial officer and executive vice president of Ultragenyx Pharmaceutical Inc. She brings more than 20 years of experience in the life sciences industry covering strategic financial planning, corporate and business development, risk analysis and investor relations. She has been chief financial officer at Ultragenyx Pharmaceutical Inc. Prior to this role, she was chief financial officer at Agenus Inc. She is a member of the board of directors of Array BioPharma Inc. She is also a member of the board of directors of the TB Alliance, a non-profit organisation advancing the development and distribution of tuberculosis treatments in the developing world. Before joining Agenus Inc., she worked in corporate strategy and corporate development at Elan Pharmaceuticals plc, was a management consultant at McKinsey & Company, and was an investment banker at Goldman Sachs, always specialising in pharmaceuticals and medical devices.

Bill Newell, Sutro's chief executive officer, said, 'Ms Sharp arrives at a key time for the company as we continue to fortify our leadership and board team with accomplished individuals well-versed in the life sciences industry. Her expertise and background are an ideal complement to our board of directors. We believe her financial and strategic guidance will be of great value to Sutro as we drive forward our internal and collaborative efforts to develop next-generation cancer therapeutics.'